Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"

[...]the two studies used different methods to consider the association between clinical outcomes and bevacizumab interruption. [...]as mentioned in a separate analysis in the efficacy section of our article (page 6) [1], we performed a landmark analysis in patients who received atezolizumab + bevac...

Full description

Saved in:
Bibliographic Details
Published in:Liver cancer (Basel ) 2024-12, Vol.13 (6), p.671-3
Main Authors: Kudo, Masatoshi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Koga, Hironori, Nakagawa, Yuki, Ikeda, Masafumi
Format: Article
Language:English
Subjects:
Bias
Clinical outcomes
Conflicts of interest
Liver cancer
Medical prognosis
Pharmaceuticals
Reply
Research funding
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]the two studies used different methods to consider the association between clinical outcomes and bevacizumab interruption. [...]as mentioned in a separate analysis in the efficacy section of our article (page 6) [1], we performed a landmark analysis in patients who received atezolizumab + bevacizumab for at least 3 months and observed similar trends as those seen in the 6-month landmark analysis. [...]party editorial support for this response was provided by Bena Lim, PhD, CMPP, of Nucleus Global, an Inizio Company.
ISSN:2235-1795
1664-5553
DOI:10.1159/000539205